8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      The CDK9 inhibitor, alvocidib, potentiates the non-clinical activity of azacytidine or decitabine in an MCL-1-dependent fashion, supporting clinical exploration of a decitabine and alvocidib combination. Abstracts of the 74th Annual Meeting of the American Society of Hematology

      Blood

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Author and article information

          Journal
          10.1182/blood-2018-99-119793

          Comments

          Comment on this article